Cargando…

血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析

BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the survival of advanced lung adenocarcinoma patients harboring EGFR mutation. Limited to the standards of tumor tissue samples and detection methods, still some people can't...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973368/
https://www.ncbi.nlm.nih.gov/pubmed/28935011
http://dx.doi.org/10.3779/j.issn.1009-3419.2017.09.01
_version_ 1783326611702022144
collection PubMed
description BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the survival of advanced lung adenocarcinoma patients harboring EGFR mutation. Limited to the standards of tumor tissue samples and detection methods, still some people can't receive target therapy following genetic guidance. This study was to explore the relevance between serum tumor markers and treatment of EGFR-TKIs. METHODS: We retrospectively collected the clinical information of advanced lung adenocarcinoma patients harboring EGFR mutation, who received EGFR-TKIs as first-line therapy from June 2009 to June 2014 in Peking University Cancer Hospital, analyzed the relationship between serum tumor markers and efficacy of EGFR-TKIs. RESULTS: The objective response rate (ORR) was 52.8% and the disease control rate (DCR) was 89.3%. The results showed that, patients with high CEA level before treatment responded better to TKIs (ORR 61.3% vs 35.9%, DCR 95.2% vs 74.4%, P < 0.001). Similar phenomena was found in patients with CEA decreased 1 month later (61.5% vs 25%, P=0.002). Progression-free survival (PFS) significantly prolonged in patients with elevated baseline CEA (mPFS 9.8 mo vs 5.9 mo, P=0.027). To the opposite, PFS was significantly shorter in patients with elevated baseline CYFRA21-1 and CA125 (mPFS 9.0 mo vs 11.4 mo, P=0.029; 9.0 mo vs 11.5 mo, P=0.023, respectively). Multivariate analysis showed that Eastern Cooperative Oncology Group (ECOG) score of 0-1, normal baseline CYFRA21-1 and CEA decline predicted longer PFS. The overall survival (OS) was highly associated with elevated CYFRA21-1 and CA125 (median OS 25.1 mo vs 52.5 mo, P=0.003; 22.7 mo vs 55.0 mo, P < 0.001, respectively), while independent of CEA. CONCLUSION: High level of baseline CEA and decline 1 month after treatment could predict the efficacy of EGFR-TKIs in patients with advanced lung adenocarcinoma. While high levels of baseline CYFRA21-1 and CA125 indicated shortened survival.
format Online
Article
Text
id pubmed-5973368
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59733682018-07-06 血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the survival of advanced lung adenocarcinoma patients harboring EGFR mutation. Limited to the standards of tumor tissue samples and detection methods, still some people can't receive target therapy following genetic guidance. This study was to explore the relevance between serum tumor markers and treatment of EGFR-TKIs. METHODS: We retrospectively collected the clinical information of advanced lung adenocarcinoma patients harboring EGFR mutation, who received EGFR-TKIs as first-line therapy from June 2009 to June 2014 in Peking University Cancer Hospital, analyzed the relationship between serum tumor markers and efficacy of EGFR-TKIs. RESULTS: The objective response rate (ORR) was 52.8% and the disease control rate (DCR) was 89.3%. The results showed that, patients with high CEA level before treatment responded better to TKIs (ORR 61.3% vs 35.9%, DCR 95.2% vs 74.4%, P < 0.001). Similar phenomena was found in patients with CEA decreased 1 month later (61.5% vs 25%, P=0.002). Progression-free survival (PFS) significantly prolonged in patients with elevated baseline CEA (mPFS 9.8 mo vs 5.9 mo, P=0.027). To the opposite, PFS was significantly shorter in patients with elevated baseline CYFRA21-1 and CA125 (mPFS 9.0 mo vs 11.4 mo, P=0.029; 9.0 mo vs 11.5 mo, P=0.023, respectively). Multivariate analysis showed that Eastern Cooperative Oncology Group (ECOG) score of 0-1, normal baseline CYFRA21-1 and CEA decline predicted longer PFS. The overall survival (OS) was highly associated with elevated CYFRA21-1 and CA125 (median OS 25.1 mo vs 52.5 mo, P=0.003; 22.7 mo vs 55.0 mo, P < 0.001, respectively), while independent of CEA. CONCLUSION: High level of baseline CEA and decline 1 month after treatment could predict the efficacy of EGFR-TKIs in patients with advanced lung adenocarcinoma. While high levels of baseline CYFRA21-1 and CA125 indicated shortened survival. 中国肺癌杂志编辑部 2017-09-20 /pmc/articles/PMC5973368/ /pubmed/28935011 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.09.01 Text en 版权所有©《中国肺癌杂志》编辑部2017 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析
title 血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析
title_full 血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析
title_fullStr 血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析
title_full_unstemmed 血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析
title_short 血清肿瘤标志物与一线EGFR-TKIs治疗晚期EGFR突变型肺腺癌患者疗效相关性分析
title_sort 血清肿瘤标志物与一线egfr-tkis治疗晚期egfr突变型肺腺癌患者疗效相关性分析
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973368/
https://www.ncbi.nlm.nih.gov/pubmed/28935011
http://dx.doi.org/10.3779/j.issn.1009-3419.2017.09.01
work_keys_str_mv AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī
AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī
AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī
AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī
AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī
AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī
AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī
AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī
AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī
AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī
AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī
AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī
AT xuèqīngzhǒngliúbiāozhìwùyǔyīxiànegfrtkiszhìliáowǎnqīegfrtūbiànxíngfèixiànáihuànzhěliáoxiàoxiāngguānxìngfēnxī